SEMAGLUTIDE GENERICS EXPAND INDIA’S GLP-1 DRUG MARKET
Why in the News?
- The launch of generic versions of semaglutide has led to a 75% rise in sales of GLP-1 drugs in India within one month.
- Sales volume of semaglutide increased from 25,000 units in February to 1.7 lakh units in April 2026 after patent expiry of Novo Nordisk products.
Growth of the GLP-1 drug market
- Rapid market expansion: Overall sales of GLP-1 injectables rose from 2.35 lakh units in February to 4.14 lakh units in April.
- Role of generics: Generic semaglutide sales jumped from zero to 1.37 lakh units within weeks of launch.
- Patent expiry impact: Availability increased after the expiry of Novo Nordisk’s patent on semaglutide in March 2026.
- Market leaders: Torrent Pharmaceuticals emerged as the leading generic manufacturer, followed by Zydus Lifesciences and Lupin Limited.
- Affordability factor: Reduced prices improved access and significantly expanded the diabetes and obesity treatment market.
Significance and health implications
- Treatment of obesity and diabetes: GLP-1 drugs are increasingly used for managing Type-2 diabetes and obesity.
- Mechanism of action: These medicines mimic incretin hormones, improving insulin secretion and reducing appetite.
- Semaglutide vs Tirzepatide: Semaglutide targets GLP-1, while tirzepatide targets both GLP-1 and GIP hormones.
- Public health relevance: Rising obesity and diabetes burden in India is increasing demand for advanced therapies.
- Pharmaceutical competition: Generic entry has expanded the market instead of significantly reducing innovator drug demand.
| GLP-1 drugs and obesity management |
| ● GLP-1 drugs: A class of medicines used for blood sugar control and weight management. |
| ● Common drugs: Includes Semaglutide, Tirzepatide, and Liraglutide. |
| ● Benefits: Help reduce blood glucose, delay gastric emptying, and promote weight loss. |
| ● Concerns: High cost, long-term safety, accessibility, and overuse for cosmetic weight loss. |
| ● UPSC relevance: Important for public health, pharmaceutical industry, patent regime, and healthcare economics under GS Paper II and III. |